In contrast, in the domain of psychiatry, clinically relevant biomarkers are scarce. For a few uncommon, Mendelian disorders such as Fragile X syndrome and Huntington’s disease, genetic testing is available. Recent work by Guintivano and colleagues has demonstrated that some psychiatric conditions such as suicidality may have emerging biomarkers, but such findings are not yet well-validated [15]. Similarly, pharmacogenomics, the study of differential response to medication treatment due to inborn differences in metabolism, is a developing field with potential relevance in psychiatry that has yet to prove its clinical relevance [16].
